Small Antibody Component Highly Effective Against SARS-CoV-2

Researchers at the University of Pittsburgh School of Medicine have isolated the smallest biological molecule to date that completely and specifically neutralizes SARS-CoV-2. This antibody component is 10 times smaller than a full-sized antibody and has been used to construct a drug known as Ab8 for potential use as a therapeutic and prophylactic against SARS-CoV2-2. The tiny antibody component is the variable, heavy chain (VH) domain of an immunoglobulin.

It was found by searching in a pool of more than 100 billion potential candidates using the SARS-CoV-2 spike protein as bait. Ab8 is created when the  VH domain is fused to a part of the immunoglobulin tail region, adding the immune functions of a full-size antibody without the bulk. Ab8 was tested using live SARS-CoV-2 and at very low concentrations it blocked the virus from entering the cells. Even at the lowest doses, Ab8 decreased by 10-fold the amount of infectious virus in those mice compared to their untreated counterparts. It was also effective in hamsters. 

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.sciencedirect.com/science/article/pii/S009286742031148X